Sunday 18 October 2026
Export ALMR’s income statement to Excel — free account
Alamar Biosciences, Inc.
ALMR
Alamar Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $74.2 million, up 195.2% from fiscal 2024. Insiders bought in the last twelve months.
25.28
2.14
−7.80%
Follow ALMR
| Older periods | Jun '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+2 more quarters Free account |
0.00 | — | 0.00 | 0.00 |
P/S ratio |
0.00 | — | 0.00 | 18.76 | |
P/FCF ratio |
0.00 | — | 0.00 | 0.00 | |
P/Operating CF |
(13.26) | — | (13.26) | (140.37) | |
P/B ratio |
0.00 | — | 0.00 | 5.08 | |
Price to Tangible BV |
0.00 | — | 0.00 | 5.11 | |
EV/Sales |
0.00 | — | 0.00 | 15.93 | |
EV/EBITDA |
0.00 | — | 0.00 | 0.00 | |
EV/Operating CF |
(2.83) | — | (2.83) | (13.89) | |
EV/FCF |
(2.64) | — | (2.64) | (12.55) | |
Quick Ratio |
— | 1.80 | 3.50 | 9.67 | |
Current Ratio |
— | 3.99 | 5.88 | 11.85 | |
Net Debt/EBITDA |
0.00 | 0.00 | (0.93) | 19.26 | |
Debt/Assets |
0.00% | 7.01% | 40.21% | 2.54% | |
Debt/Equity |
0.00 | 0.13 | 1.32 | 0.03 | |
Asset Turnover |
— | — | 0.00 | 0.43 | |
Operating CF/Net income |
1.69 | 0.00 | 0.95 | 0.86 | |
Capex/Depreciation |
(0.79) | (1.37) | (0.49) | (3.41) | |
Interest Coverage |
(164.98) | — | (55.37) | (60.41) | |
Research and Development Expense of Revenue |
55.04% | — | 50.00% | 46.95% | |
Selling, General and Administrative Expense of Revenue |
47.05% | — | 52.96% | 59.24% | |
Intangible Assets out of Total Assets |
0.00 | 0.01 | 0.01 | 0.00 | |
Share Based Compensation of Revenue |
4.21% | — | 5.63% | 11.15% | |
Graham Net Nets |
0.04 | — | 0.04 | 0.16 | |
Graham Number |
0.00 | — | 0.00 | 0.00 | |
Earnings Yield |
(12.02%) | — | (12.02%) | (12.02%) | |
Free Cash Flow Yield |
(39.37%) | — | (39.37%) | (6.77%) | |
Revenue per Share |
1.42 | — | 2.12 | 0.50 | |
Operating CF per Share |
(1.04) | 0.00 | (1.66) | (0.19) | |
Capex per Share |
(0.07) | 0.00 | (0.05) | (0.06) | |
Free Cash Flow per Share |
(1.11) | 0.00 | (1.71) | (0.26) | |
Cash per Share |
0.00 | 0.00 | 5.27 | 4.26 | |
Shareholders Equity per Share |
0.00 | 0.00 | 4.64 | 5.33 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 0.00 | 4.64 | 5.33 | |
Free Cash Flow |
(12.63) | (58.98) | (20.95) | (14.96) | |
Working Capital |
— | 70.98 | 117.43 | 303.42 | |
Capital Expenditures |
(0.75) | (5.37) | (0.60) | (3.64) | |
Net Current Asset Value |
0.00 | 30.76 | 11.95 | 253.26 | |
EV/EBIT |
0.00 | — | 0.00 | 0.00 | |
Capex to Sales |
0.05 | 0.00 | 0.02 | 0.12 | |
Price to Operating Income |
0.00 | — | 0.00 | 0.00 | |
| Other line items | |||||
Average Assets |
— | — | 167.98 | 195.49 |
Columns are period end dates